Philogen Provides Corporate Update
Philogen Provides Corporate Update 211 out of 214 patients recruited in European Phase III trial investigating the neoadjuvant Nidlegy treatment of Stage IIIB/C melanoma, in line with expectations.Fibromun further
Source: finanznachrichten.de
